Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Shanghai Stock Exchange  >  Jiangsu Hengrui Medicine Co., Ltd.    600276   CNE0000014W7

JIANGSU HENGRUI MEDICINE CO., LTD.

(600276)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Shanghai Stock Exchange
01/18/2021 01/19/2021 01/20/2021 01/21/2021 01/22/2021 Date
107.83 104.95 105.97 108.15 112.6 Last
23513190 34814220 30502720 38293450 41130790 Volume
-1.82% -2.67% +0.97% +2.06% +4.11% Change
Financials
Sales 2020 28 624 M 4 417 M 4 417 M
Net income 2020 6 433 M 993 M 993 M
Net cash position 2020 14 071 M 2 171 M 2 171 M
P/E ratio 2020 92,1x
Yield 2020 0,18%
Sales 2021 35 851 M 5 532 M 5 532 M
Net income 2021 8 210 M 1 267 M 1 267 M
Net cash position 2021 18 325 M 2 828 M 2 828 M
P/E ratio 2021 71,9x
Yield 2021 0,23%
Capitalization 598 B 92 231 M 92 238 M
EV / Sales 2020 20,4x
EV / Sales 2021 16,2x
Nbr of Employees 24 431
Free-Float 39,2%
More Financials
Company
Jiangsu Hengrui Medicine Co., Ltd. specializes in the research, development, manufacture and marketing of pharmaceutical products. The activity is organized primarily around 5 families of products: - anti-tumor drugs (No. 1 Chinese); - Anesthetic drugs; - contrast agents: used in medical imaging; - anti-inflammatory drugs; - drugs for the treatment of cardiovascular diseases. 
Sector
Pharmaceuticals
Calendar
04/20Earnings Release
More about the company
Notations Surperformance© of Jiangsu Hengrui Medicine Co., Ltd.
Trading Rating : Investor Rating :
More Ratings
All news about JIANGSU HENGRUI MEDICINE CO., LTD.
2020Drugmakers agree to halve prices to get on China state insurance list
RE
2020Chinese Shares Rebound at Close; Jiangsu Hengrui Medicine Jumps 8% on Clinica..
MT
2020JIANGSU HENGRUI MEDICINE : Nine-Month Net Profit Rose 14%
DJ
2020JIANGSU HENGRUI MEDICINE CO., LTD. : quaterly earnings release
2020Stymied at home, Korea's mom and pop investors charge into China tech stocks
RE
2020Stymied at home, Korea's mom and pop investors charge into China tech stocks
RE
2020THERMO FISHER SCIENTIFIC : Signs Companion Diagnostic Agreement with Hengrui The..
AQ
2020JIANGSU HENGRUI MEDICINE CO., LTD. : 20% Stock Dividend
FA
2020JIANGSU HENGRUI MEDICINE CO., LTD. : Ex-dividend day for final dividend
FA
2020JIANGSU HENGRUI MEDICINE CO., LTD. : quaterly earnings release
2020JIANGSU HENGRUI MEDICINE CO., LTD. : annual earnings release
2020How a virus impacts the economy and markets
RE
2019JIANGSU HENGRUI MEDICINE : Mycovia Pharmaceuticals and Jiangsu Hengrui Medicine ..
BU
2019JIANGSU HENGRUI MEDICINE CO. : 20% Stock Dividend
FA
2019JIANGSU HENGRUI MEDICINE CO. : Ex-dividend day for final dividend
FA
More news
News in other languages on JIANGSU HENGRUI MEDICINE CO., LTD.
2020JIANGSU HENGRUI MEDICINE CO., LTD. : Veröffentlichung des Quartalsergebnisses
2020JIANGSU HENGRUI MEDICINE CO., LTD. : publication des résultats trimestriels
2020JIANGSU HENGRUI MEDICINE CO., LTD. : Veröffentlichung des Quartalsergebnisses
2020JIANGSU HENGRUI MEDICINE CO., LTD. : publication des résultats trimestriels
2020VALEURS MOYENNES DU BTP : Après l'arrêt total, la reprise des chantiers reste co..
More news
Chart JIANGSU HENGRUI MEDICINE CO., LTD.
Duration : Period :
Jiangsu Hengrui Medicine Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JIANGSU HENGRUI MEDICINE CO., LTD.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 24
Average target price 108,71 CNY
Last Close Price 112,60 CNY
Spread / Highest target 14,6%
Spread / Average Target -3,46%
Spread / Lowest Target -33,5%
EPS Revisions
Managers and Directors
NameTitle
Yun Shu Zhou Chairman & General Manager
Wei Dong Chairman-Supervisory Board
Song Zhou Chief Financial Officer
Jie Ping Sun Director & Deputy General Manager
Hong Bin Dai Director & Deputy General Manager
Sector and Competitors
1st jan.Capitalization (M$)
JIANGSU HENGRUI MEDICINE CO., LTD.1.02%92 231
JOHNSON & JOHNSON3.92%430 552
ROCHE HOLDING AG3.06%308 615
NOVARTIS AG2.73%220 726
MERCK & CO., INC.-1.00%204 882
PFIZER INC.-0.71%203 159